Vytrus Biotech, S.A. (BME:VYT)
Spain
· Delayed Price · Currency is EUR 3.300
0.00 (0.00%)
At close: May 9, 2025, 5:30 PM CET
Vytrus Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 5.24 | 4.7 | 4.48 | 3.51 | 2.23 | 1.77 | Upgrade
|
| Revenue Growth (YoY) | 14.24% | 4.90% | 27.57% | 57.47% | 25.74% | 39.69% | Upgrade
|
| Cost of Revenue | 0.49 | 0.35 | 0.35 | 0.26 | 0.11 | 0.2 | Upgrade
|
| Gross Profit | 4.75 | 4.35 | 4.13 | 3.25 | 2.12 | 1.58 | Upgrade
|
| Selling, General & Admin | 3.43 | 3.29 | 2.86 | 2.29 | 1.57 | 0.76 | Upgrade
|
| Other Operating Expenses | -0.07 | -0.07 | -0.03 | -0.02 | -0.04 | 0.63 | Upgrade
|
| Operating Expenses | 4.11 | 3.94 | 3.52 | 2.84 | 1.92 | 1.74 | Upgrade
|
| Operating Income | 0.63 | 0.4 | 0.61 | 0.41 | 0.2 | -0.16 | Upgrade
|
| Interest Expense | -0.13 | -0.15 | -0.2 | -0.12 | -0.12 | -0.1 | Upgrade
|
| Interest & Investment Income | 0.01 | 0.01 | 0.01 | - | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0.01 | -0 | -0 | -0 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | 0.03 | 0.03 | 0.02 | - | -0.07 | Upgrade
|
| EBT Excluding Unusual Items | 0.54 | 0.29 | 0.44 | 0.31 | 0.08 | -0.32 | Upgrade
|
| Asset Writedown | - | - | - | -0 | -0.03 | - | Upgrade
|
| Other Unusual Items | 0.01 | 0.02 | 0.01 | 0 | -0 | - | Upgrade
|
| Pretax Income | 0.56 | 0.31 | 0.45 | 0.31 | 0.09 | -0.32 | Upgrade
|
| Income Tax Expense | -0.14 | -0.24 | -0.15 | -0.14 | -0.13 | -0.25 | Upgrade
|
| Net Income | 0.7 | 0.54 | 0.61 | 0.45 | 0.22 | -0.07 | Upgrade
|
| Net Income to Common | 0.7 | 0.54 | 0.61 | 0.45 | 0.22 | -0.07 | Upgrade
|
| Net Income Growth | 10.80% | -9.96% | 34.49% | 107.48% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 8 | 7 | - | 7 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 8 | 7 | - | 7 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | 11.10% | - | - | 0.43% | -0.92% | - | Upgrade
|
| EPS (Basic) | 0.09 | 0.08 | - | 0.06 | 0.03 | -0.01 | Upgrade
|
| EPS (Diluted) | 0.09 | 0.08 | - | 0.06 | 0.03 | -0.01 | Upgrade
|
| EPS Growth | -0.27% | - | - | 106.59% | - | - | Upgrade
|
| Free Cash Flow | 1.32 | 0.76 | 0.61 | 0.23 | -0.32 | - | Upgrade
|
| Free Cash Flow Per Share | 0.17 | 0.11 | - | 0.03 | -0.05 | - | Upgrade
|
| Gross Margin | 90.61% | 92.46% | 92.14% | 92.60% | 94.98% | 88.96% | Upgrade
|
| Operating Margin | 12.08% | 8.60% | 13.53% | 11.65% | 8.82% | -9.09% | Upgrade
|
| Profit Margin | 13.30% | 11.59% | 13.50% | 12.81% | 9.72% | -4.10% | Upgrade
|
| Free Cash Flow Margin | 25.15% | 16.22% | 13.51% | 6.47% | -14.15% | - | Upgrade
|
| EBITDA | 1.39 | 1.13 | 1.3 | 0.99 | 0.59 | 0.2 | Upgrade
|
| EBITDA Margin | 26.49% | 24.02% | 28.97% | 28.06% | 26.51% | 11.02% | Upgrade
|
| D&A For EBITDA | 0.75 | 0.73 | 0.69 | 0.58 | 0.39 | 0.36 | Upgrade
|
| EBIT | 0.63 | 0.4 | 0.61 | 0.41 | 0.2 | -0.16 | Upgrade
|
| EBIT Margin | 12.08% | 8.60% | 13.53% | 11.65% | 8.82% | -9.09% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.